Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.32 AUD
Change Today +0.025 / 8.47%
Volume 1.2M
UNS On Other Exchanges
As of 1:58 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

unilife corp-cdi (UNS) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/11/15 - A$1.00
52 Week Low
08/24/15 - A$0.26
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for UNILIFE CORP-CDI (UNS)

Related News

No related news articles were found.

unilife corp-cdi (UNS) Related Businessweek News

View More BusinessWeek News

unilife corp-cdi (UNS) Details

Unilife Corporation designs, manufactures, and supplies injectable drug delivery systems in the United States and internationally. The company offers Unifill, a pre-filled syringe with integrated, automatic, and user-controlled retraction; Unifill Finesse, an integrated, automatic, and user-controlled retraction with standard plunger seal and plunger rod; Unifill Select, which allows an end-user to select and attach a needle at the time of injection; Unifill Nexus that is equipped with an integrated luer adapter to provide connectivity with needleless luer access devices; and Unifill Allure, which combines universal luer connectivity with automatic, user-controlled needle retraction. It also provides ReadyToGo platform of wearable injectors designed for pre-filled, disposable devices that can be worn by a patient over periods during the subcutaneous injection of therapies; LISA smart reusable auto-injector; and RITA disposable auto-injector, an ergonomic single-use product. In addition, the company offers drug reconstitution delivery systems, including AutoMix Presto, an automatic reconstitution for single-step mixing and injection; EZMix Genesis, a ventless one-step reconstitution and automatic user-controlled retraction; EZMix Engage, a one step reconstitution to attach and retract a needle; and EZMix Prodigy, a single-barrel reconstitution system with a pre-fillable syringe. Further, it provides ocular delivery systems comprising Ocu-ject for the delivery of microliter sized doses to the eye; Ocu-mix, a dual-chamber syringe platform to reconstitute or mix, and deliver various therapies into the eye with a single injection; and Depot-ject, which places a drug depot into the eye. Additionally, the company offers Micro-ject to optimize the delivery of therapies with microliter doses that are unsuited to conventional device technologies. It serves pharmaceutical and biotechnology companies. The company was founded in 2002 and is headquartered in York, Pennsylvania.

278 Employees
Last Reported Date: 08/31/15
Founded in 2002

unilife corp-cdi (UNS) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: $630.0K
President and Chief Operating Officer
Total Annual Compensation: $726.0K
Chief Compliance Officer and Vice President o...
Total Annual Compensation: $308.0K
Senior Vice President and Controller
Total Annual Compensation: $308.0K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $52.3K
Compensation as of Fiscal Year 2014.

unilife corp-cdi (UNS) Key Developments

Unilife Corporation Reports Consolidated Earnings Results for the Full Year Ended June 30, 2015

Unilife Corporation reported consolidated earnings results for the full year ended June 30, 2015. For the year, the company reported revenues were USD 13,158,000 against USD 14,689,000 a year ago. Operating loss was USD 80,428,000 against USD 51,395,000 a year ago. Net loss was USD 90,849,000 or USD 0.81 basic and diluted loss per share against USD 57,899,000 or USD 0.59 basic and diluted loss per share a year ago. Net cash used in operating activities was USD 55,201,000 against USD 36,601,000 a year ago. Purchases of property, plant and equipment was USD 16,633,000 against USD 12,149,000 a year ago. Revenues decreased due to less revenue recognized related to development activities for various customers primarily due to the timing of when milestones are achieved. The increase in the net loss was primarily attributable to higher research and development expenses to support ongoing and future customer programs including increased payroll and related cost as well as material and tooling costs. To a lesser extent the increased net loss was also due to higher selling, general and administrative expenses, primarily legal and professional fees, and higher change in fair value of the royalty liability.

Unilife Corporation Announces Board Changes

Unilife Corporation announced the appointment of Mr. Harry Hamill to the Board of Directors, the appointment of Ms. Mary Kate Wold as Lead Independent Director, and the retirement of Mr. Jim Bosnjak after 12 years of service. Mr. Hamill is a seasoned financial executive in the public company life sciences sector, who prior to his retirement held several senior finance positions at Wyeth. During Mr. Hamill's 18-year career at Wyeth, he held various executive roles, including leading global Mergers and Acquisitions, Vice-President of Finance for Wyeth's global manufacturing and distribution operations, CFO of a global animal health business unit, and Corporate Vice President and Deputy Controller. Ms. Mary Kate Wold, who joined the Unilife Board in 2010 and is Chief Executive Officer of the Church Pension Fund, has been appointed as Vice Chair and Lead Independent Director. She will also continue to serve as Chair of the Strategic Partnerships Committee and as a member of the Audit Committee and Nominating and Governance Committee. Mr. Jim Bosnjak has advised Unilife of his decision to retire from the Board for health reasons.

Former Employee Withdraws Whistleblower Lawsuit Against Unilife Corporation

Unilife Corporation announced that a former employee has agreed to dismiss all of his claims against the company and has issued a public apology for bringing his claims. The case, Talbot Smith v. Unilife Corp. et al, No. 13-CV-05101, filed in the United States District Court for the Eastern District of Pennsylvania, has been dismissed in its entirety with prejudice.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UNS:AU A$0.32 AUD +0.025

UNS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $136.72 USD +1.83
West Pharmaceutical Services Inc $55.65 USD +0.96
Ypsomed Holding AG SFr.105.50 CHF +0.50
View Industry Companies

Industry Analysis


Industry Average

Valuation UNS Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UNILIFE CORP-CDI, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at